iTIND: the second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia

Abstract

iTIND is the second-generation version of the temporary nitinol implantable device (TIND), which has emerged over the past decade as one of the latest additions to the library of minimally invasive surgeries now available to treat bothersome lower urinary tract symptoms (LUTS) caused by benign prostate enlargement. While the key procedural steps remain the same, it now carries specific modifications designed to improve its efficacy and safety profile further. With the option to perform implantation under local anaesthesia, it can be delivered on an ambulatory basis and in the office setting. While the formal position of iTIND in current guidelines is yet to be determined, 12-month data demonstrates that it can improve both objective and subjective outcome measures, which are sustained at short-term follow up.

Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques

“…8. Future Modalities 8.1. iTind iTind is a temporary implantable nitinol device that has three struts at the 12, 5 and 7 o'clock positions with an anchoring leaflet and is deployed under direct visualisation within the prostatic urethra [98]. The device exerts continuous pressure and therefore creates ischaemic necrosis resulting in remodelling of the prostatic urethra and bladder neck, and is removed after 5 days via cystoscopy.…”

Surgical treatment options for benign prostatic obstruction: beyond prostate volume

“…The novel temporary implantable nitinol device, or iTind, received FDA approval in 2020. The second-generation device uses three struts to gradually expand tissue through ischemic necrosis over 5–7 days of placement prior to device removal [29,30 ▪ ,31]. Six months following the procedure in the MT-06 study, the 70 patients who underwent iTind did not experience any change in erectile or ejaculatory function and even reported improvements in MSHQ-EjD scores (9.2–11.2; P < 0.01).…”

Modern advancements in minimally invasive surgical treatments for benign prostatic obstruction

“…These channels and the overall remodelling process reduces bladder outflow obstruction and subsequent LUTS. 40 At present, neither NICE, the AUA or EAU offer any specific guidance on the use of iTIND, other than the EAU suggesting the need for RCT level evidence to a reference technique. 14 At present, there is no RCT comparing iTIND with TURP.…”

“…These channels and the overall remodelling process reduces bladder outflow obstruction and subsequent LUTS. 40 …”